Pathology

病理核心旨在为项目研究人员提供专家 所有表现为斯隆-凯特琳癌的软组织肉瘤的病理学评价 中心。该中心将为以组织为基础的研究提供一个集中、全面的设施。该资源将 以公平和道德的方式提供组织和相关数据，提供专业知识 组织和分子病理学，协助和执行基于组织的实验。人体组织 用于研究的药物是根据现有的IRB批准的方案获得的。具体目标是： 1.为提供在MSKCC切除的所有STS标本的一致的、专家的病理特征， 包括大体外观、组织学类型、肿瘤分级、坏死和手术切缘的描述。 2.监督正常和肿瘤人体组织样本的采购，并维持 冷冻肉瘤组织，用于在不同项目下进行的特殊研究。这一过程确保了 足够量的正确识别和处理的组织送到适当的实验室。 3.为个别项目提供专家组织学审查，包括肿瘤生存能力和评估 不同研究中使用的不同研究药物对肿瘤的反应，无论是在治疗后的手术中 标本或异种移植。还将提供对各种抑制剂的组织学反应评估 临床前活体小鼠模型，以及小鼠基因敲除/转基因模型的组织学专业知识。 4.协助进行高通量组织芯片(TMA)和免疫组织化学解释 (IHC)和原位杂交研究(ISH)，用于各种微阵列项目的验证研究。一架ATA-27 Beecher自动组织阵列将用于构建不同肉瘤类型的TMA和 伴随着正常组织。IHC/ISH结果的定量图像分析将使用 ACIS II(自动细胞成像系统)Chromavision玻片扫描仪组织阵列。协助 将由生物信息学核心开发临床组织微阵列(ClinTMA)数据库 结果将以连续值的形式输入该数据库。 这些目标为STS计划项目提供了实质性的基础设施，并允许核心B提供 以具有成本效益的方式提供所需的服务。

The Pathology Core is designed to provide the investigators of the Program Project with expert pathologic evaluation of all soft tissue sarcomas (STS) that present to Memorial Sloan-Kettering Cancer Center. The Core will provide a centralized, comprehensive facility for tissue-based research. The resource will provide tissues and associated data in an equitable and ethical manner, provide professional expertise in histo- and molecular pathology and assist and perform tissue-based experimentation. The human tissues used for research studies are obtained under existing IRB-approved protocols. The specific aims are: 1. To provide consistent, expert pathologic characterization of all STS specimens resected at MSKCC, including a description of gross appearance, histologic type, tumor grade, necrosis, and surgical margins. 2. To supervise the procurement of normal and neoplastic human tissue samples and maintain a bank of frozen sarcoma tissue for special studies conducted under the different projects. This process ensures that adequate amounts of correctly identified and processed tissue reach the appropriate laboratories. 3. To provide expert histologic review for individual projects, including tumor viability and assessment of tumor response to various investigational agents used in different studies, either in post-treated surgical specimens or xenografts. Histologic response assessment to various inhibitors will also be provided for the preclinical in vivo mouse models, as well as histologic expertise for the murine knockout/transgenic models . 4. To assist in performing high-throughput tissue microarray (TMA) and interpreting immunohistochemical (IHC) and in situ hybridization studies (ISH) for validation studies of various microarray projects. An ATA-27 Beecher Automated tissue arrayer will be used to construct TMAs of varying sarcoma types and accompanying normal tissues. Quantitative image analysis of the IHC/ISH results will be performed using an ACIS II (automated cellular imaging system) Chromavision slide scanner tissue arrayer. Assistance with the development of the Clinical Tissue Microarray (ClinTMA) Database by the Bioinformatics Core will be provided, and results will be entered into this database as continuous values. These aims offer a substantial infrastructure to the STS Program Project and allows Core B to provide the required services in a cost effective manner.